Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: metformin hydrochloride 1000 mg tablets Clear all
Not listed Phase 2 Interventional

Metformin for HIV Inflammation

NCT02383563
View directory record Official record
Conditions
HIV, Coronary Artery Disease
Interventions
metformin extended release
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 7, 2026, 8:08 AM EDT
Terminated Phase 3 Interventional Results available

REMAP Trial for Optimizing Surgical Outcomes at UPMC

NCT03861767
View directory record Official record
Conditions
Aging
Interventions
Metformin ER, Placebo
Drug
Lead sponsor
Matthew Neal MD
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

NCT01002807
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Dapagliflozin, Metformin XR, Glucophage
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 7, 2026, 8:08 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

NCT05949008
View directory record Official record
Conditions
NIDDM, Obesity
Interventions
Metformin Extended Release (ER) Oral Tablet, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

NCT04231435
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fedratinib, Digoxin, Rosuvastatin, Metformin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions

NCT00778427
View directory record Official record
Conditions
Healthy
Interventions
metformin hydrochloride 1000 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

RISE Adult Medication Study

NCT01779362
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes
Interventions
Metformin, Liraglutide, Glargine, Placebo
Drug
Lead sponsor
RISE Study Group
Network
Eligibility
20 Years to 65 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

NCT03429543
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin, Insulin, Placebo, Linagliptin, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib

NCT01551615
View directory record Official record
Conditions
Healthy
Interventions
Metformin 1000 mg, Vandetanib 800 mg
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed Conditions

NCT00778466
View directory record Official record
Conditions
Healthy
Interventions
metformin hydrochloride 1000 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

NCT00951899
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam, Placebo, Diet, Metformin
Drug · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1Phase 2 Interventional

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

NCT01488552
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI
Drug · Genetic
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00374907
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 7, 2026, 8:08 AM EDT
Terminated Phase 4 Interventional Results available

Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease

NCT01901224
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Metformin 1000 mg, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 7, 2026, 8:08 AM EDT
Recruiting Phase 4 Interventional

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

NCT02915198
View directory record Official record
Conditions
Prediabetic State, Atherosclerosis, Metformin
Interventions
Metformin XR, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
7,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

NCT00897390
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Metformin IR (glucophage), Saxagliptin + Metformin IR (FDC)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

NCT06042855
View directory record Official record
Conditions
Covid19
Interventions
Placebo, Metformin
Other · Drug
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
3,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 2 Interventional

Safety and Feasibility of Metformin for Sepsis Induced AKI

NCT05900284
View directory record Official record
Conditions
Sepsis, Septic Shock, Acute Kidney Injury, Metformin
Interventions
Metformin low dose, Metformin high dose, Placebo
Drug
Lead sponsor
Hernando Gomez
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

NCT01512979
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
metformin, linagliptin, metformin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Chino, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

NCT02956044
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin, Metformin, Glimepiride, Sitagliptin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

NCT01463228
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Oct 7, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects

NCT01068730
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
metformin (Diabex), metformin (Glucophage™)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 7, 2026, 8:08 AM EDT